Key Highlights
- Net loss was USD 3.8 million for the third quarter of 2026.
- MRD-positive rate was 44% with IMNN-001, against 67% in the control group.
- An agreement was announced to sell ThermoDox rights to VoxelDox Therapeutics.
- Financing activities provided USD 10.6 million over the nine months.
Imunon (NASDAQ:IMNN) reported a third-quarter 2026 net loss of USD 3.8 million, against USD 3.4 million a year earlier. Loss per share was USD 0.64, against an estimate of USD 0.55. For the nine months, net loss was USD 10.8 million, against USD 10.3 million. The company reported no revenue.
Manufacturing and clinical Supply costs for IMNN-001 supporting the OVATION and MRD programs were USD 0.8 million in the quarter, against USD 0.9 million. The filing attributes the decrease mainly to efficiency in advancing OVATION-3.
Preliminary MRD Study Results
The filing reports preliminary results from the Phase 2 MRD study. Compared with control, IMNN-001 showed a lower MRD-positive rate, at 44% against 67%, and a higher rate of circulating tumor DNA clearance, at 87.5% against 62.5%. A numerically higher rate of patients achieved no evidence of disease following frontline therapy, at 100% against 56%.
Dr. Amir Jazaeri of MD Anderson Cancer Center, the lead principal investigator of the Phase 2 MRD study, presented the preliminary clinical and translational findings. Dr. William Bradley of the Medical College of Wisconsin, a principal investigator across OVATION-1, 2 and 3, joined a prerecorded conversation with a woman treated with IMNN-001 in OVATION-1, who reported remaining free of recurrence nearly 10 years from her diagnosis.
ThermoDox Agreement With VoxelDox
Management announced an agreement to sell its rights to ThermoDox, its heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, which intends to advance the asset in glioblastoma. Management said the company prefers to find a committed development partner for ThermoDox rather than carry it itself, and that ThermoDox is a legacy asset fully written off its balance sheet.
Under the agreement, on closing, Imunon would receive an Equity interest of approximately 4.76% in VoxelDox. It would also be eligible for up to USD 16.5 million in aggregate development and sales-based milestone payments, plus tiered royalties of 3.5% to 6% on net sales of ThermoDox-related products, if approved. The sale is contingent on VoxelDox completing a planned USD 2.5 million financing to support a Phase 1 trial in glioblastoma.
Cash Flow and Subsequent Events
Net cash used in investing activities was USD 0.1 million for the nine months, against USD 0.3 million, consisting solely of purchases of property and equipment. Net cash provided by financing activities was USD 10.6 million, against USD 9.9 million.
Subsequent to September 30, 2026, on October 27, 2026, the company filed a registration statement on Form S-1, amended on October 28, 2026, for a proposed best-efforts public offering. At September 30, 2026, USD 1.5 million of principal was outstanding under the A-1 Note, which carries 8% interest paid in kind, and USD 5.0 million under the B Note, which carries 5% interest paid in cash. Both mature in December 2027.
The reported items for the quarter are the net loss of USD 3.8 million, the preliminary MRD results, the ThermoDox agreement and the S-1 filing for a proposed public offering. Management described enrollment rates and interim analysis among the topics on the call.






Please wait processing your request...